• Fresenius unit Fresenius Kabi launched an FDA-approved generic sugammadex injection in the US in Simplist ready-to-administer prefilled syringes.
• Launch follows expiry of Merck’s Bridion exclusivity in July 2026, opening the US market to generic competition.
• Product targets operating rooms, aiming to streamline medication handling with a single-dose 200 mg/2 mL prefilled syringe format.
• Fresenius Kabi will formulate, fill, and package the product in the US, supporting supply-chain resilience and domestic manufacturing capacity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via Business Wire (Ref. ID: 202609031700BIZWIRE_USPR_____20260903_BW952886) on September 03, 2026, and is solely responsible for the information contained therein.